Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a liver drug protect the brain after a bleeding stroke?

NCT ID NCT01095731

Disease control Sponsor: E. Sander Connolly Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether tiopronin, a drug used for liver disease, can lower a harmful chemical in the brain and improve recovery after a bleeding stroke from a burst aneurysm. Sixty patients received either tiopronin or a placebo for up to 14 days. The goal was to see if the drug is safe and reduces brain damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tiopronin
What this could lead to
If it works, this could point toward a treatment that reduces brain damage after a bleeding stroke.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not improve recovery or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Start date

Apr 2010

Finished

Jul 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Admitted to a recruiting center with aneurysmal subarachnoid hemorrhage * Ability to initiate study drug treatment within 96 hours of aSAH onset. * Ability to provide either informed or surrogate consent Exclusion Criteria: * Hypersensitivity to penicillamine * Creatinine level greater than 1.5/mm\^3 on admission * Platelet count of less than 100,000/mm\^3 on admission * White blood cell count of less than 3.5/mm\^3 on admission * AST or ALT of greater than 60/L on admission or history of liver failure * Pregnancy * History of lupus, Goodpasture's syndrome, myasthenia gravis, pemphigus, nephrotic syndrome, glomerulonephritis, or renal failure * Patients considered unable to comply with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage Aneurysm brain ischemia Hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysmal subarachnoid hemorrhage

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • University of Florida

    Gainesville, Florida, 32611, United States

  • University of Washington

    Seattle, Washington, 96104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.